{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-22-000006","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2022-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.861765+00:00","generated_at":"2026-06-26T22:03:06.877150+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Black Diamond Therapeutics reports FY2021 net loss $125.6M; cash $209.8M, runway into 2024","bullets":["Net loss FY2021 $125.6M vs $67.3M YoY; Q4 loss $25.9M vs $22.6M.","Cash $209.8M at Dec 31, 2021 (down from $315.1M); sufficient to fund operations into 2024.","R&D spend $96.8M in 2021 (vs $48.2M); G&A $30.0M (vs $21.4M).","FDA allowed IND for BDTX-1535; Phase 1 study initiated for GBM and NSCLC with CNS metastases.","Appointed Elizabeth Montgomery as Chief People Officer, bringing nearly 20 years HR experience in life sciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-22-000006","json":"https://secwatch.observer/filing/0001701541-22-000006.json","markdown":"https://secwatch.observer/filing/0001701541-22-000006.md","text":"https://secwatch.observer/filing/0001701541-22-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154122000006/0001701541-22-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154122000006/bdtx-20220317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:03:06.877150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}